Varex Imaging Corporation
NASDAQ:VREXMedical - Devices
+$0.34 today
- Market cap
- $770.71M
- Beta
- 0.90
- P/E (TTM)
- -5.3
- EPS (TTM)
- -$1.97
Volume 0.73M
Average 0.36M
VREX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Varex Imaging CorporationNASDAQ: VREX
Research & Development · Q2 FY2026 · quarter ended Apr 2026
Research & development grows in line with its trailing trend
Q2 FY2026 research & development of $22.2M rose 0.9% year over year, ahead of the +0.1% change in trailing-twelve-month research & development. Sequentially, it rose 2.3% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.
Context
- Research & development amounted to 10.8% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +0.9% holds above the trailing-twelve-month pace of +0.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 91.1M USD
- Year-over-year change
- +4.7%
- 4-year CAGR
- +6.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-03 | 91.1M | +4.7% |
| FY2024 | 2024-09-27 | 87M | +2.6% |
| FY2023 | 2023-09-29 | 84.8M | +10.1% |
| FY2022 | 2022-09-30 | 77M | +7.1% |
| FY2021 | 2021-10-01 | 71.9M | — |
Research & Development vs competitors
How VREX compares with its peers on the latest reported figures
- VREX's LTM Apr 2026 research & development of $89.5M is the 3rd highest of the 5 companies compared; the peer median is $236.32M.
- Its year-over-year change of +0.1% is the 3rd highest of 5, against a peer median of -0.2%.
- Research & development amounts to 10.4% of revenue for VREX, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.32B | +1.2% | +7.1% | 6.5% | |
| LTM Jun 2026 | $393.5M | -1.6% | +18.8% | 11.2% | |
| LTM Apr 2026 | $89.5M | +0.1% | +5.8% | 10.4% | |
| LTM Jun 2026 | $79.14M | +7.8% | +10.1% | 4.4% | |
| LTM Dec 2025 | $19.24M | -4.7% | -10.1% | 147.7% | |
| Peer median (excluding VREX) | $236.32M | -0.2% | +8.6% | 8.9% | |
Competitors are the stored peer set for VREX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Oct 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Revenue | 818.1M | 859.4M | 893.4M | 811M | 844.6M |
| Cost of Revenue | 546.6M | 575.9M | 603.1M | 554.1M | 554.1M |
| Gross Profit | 271.5M | 283.5M | 290.3M | 256.9M | 290.5M |
| Gross Margin | 33.2% | 33.0% | 32.5% | 31.7% | 34.4% |
| Research & Development | 71.9M | 77M | 84.8M | 87M | 91.1M |
| Selling, General & Admin | 125.5M | 118.3M | 128.4M | 137.8M | 133.3M |
| Operating Expenses | 197.4M | 195.3M | 213.2M | 224.8M | 318.3M |
| Depreciation & Amortization | 37.3M | 33.6M | 33.2M | 31.1M | 27.2M |
| EBITDA | 104.5M | 114.5M | 94.7M | 62.9M | 3.5M |
| EBITDA Margin | 12.8% | 13.3% | 10.6% | 7.8% | 0.4% |
| Operating Income | 74.1M | 88.2M | 77.1M | 32.1M | (27.8M) |
| Operating Margin | 9.1% | 10.3% | 8.6% | 4.0% | -3.3% |
| Interest Income | 100K | 400K | 3.7M | 7.3M | 8.5M |
| Interest Expense | 43.4M | 41M | 29.3M | 31.1M | 35.5M |
| Other Income / Expenses | (45.5M) | (43.7M) | (45.8M) | (27.1M) | (31.4M) |
| Income Before Tax | 28.6M | 44.5M | 31.3M | 5M | (59.2M) |
| Pre-Tax Margin | 3.5% | 5.2% | 3.5% | 0.6% | -7.0% |
| Income Tax Expense | 10.7M | 13.7M | (16.6M) | 52.2M | 10.7M |
| Net Income | 17.4M | 30.3M | 47.4M | (47.7M) | (70.3M) |
| Net Margin | 2.1% | 3.5% | 5.3% | -5.9% | -8.3% |
| EPS (Basic) | 0.44 | 0.76 | 1.20 | (1.17) | (1.70) |
| EPS (Diluted) | 0.43 | 0.73 | 0.96 | (1.17) | (1.70) |
| Weighted Avg Shares | 39.3M | 39.8M | 40.3M | 40.8M | 41.4M |
| Weighted Avg Shares (Diluted) | 40.3M | 41.6M | 50.3M | 40.8M | 41.4M |
Varex Imaging Corporation
NASDAQ:VREX
Intrinsic Alpha fair value
Locked
Current Price
$18.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.